HER2-mutant NSCLC

Baili Pharma

Baili Pharma’s BL-M07D1 Enters Phase III in HER2-Mutant NSCLC, Challenging Keytruda Head-On

Baili Pharma has launched a head-to-head Phase III trial of BL-M07D1 versus Keytruda + chemo in first-line HER2-mutant NSCLC, a bold challenge to the current standard. Baili is also advancing Iza-Bren, an EGFR/HER3 ADC with strong Phase II results.